BioCardia touts preliminary data from heart failure trial

BioCardia (OTC:BCDA) touted data today from the first 10 patients treated in its Phase III CardiAmp heart failure trial.

The company’s investigational therapy uses a patient’s bone marrow cells to trigger the body’s natural ability to heal itself, according to BioCardia. These data are the first to be published from any pivotal trial of a stem cell therapy for heart failure, the company noted.

Get the full story at our sister site, Drug Delivery Business News.

The post BioCardia touts preliminary data from heart failure trial appeared first on MassDevice.

from MassDevice https://ift.tt/2NaVQ5H